← Leaderboards
Vincent A Miller
Sloan-Kettering Institute For Cancer Res
$902,822
Attributed
$902,822
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $232.4K · FY2005–08$250K$187.5K$125K$62.5K$0
'05
'06
'07
'08
Funding mix
By agency
NIH$902,822 · 2
By mechanism
R21$902,822 · 2
Top collaborators
No co-investigators on record.
Most similar at Sloan-Kettering Institute For Cancer Res
Same institution · by research overlap
- Marc Ladanyi$28,443,479
- Joan Massague$31,163,003
- William Pao$4,438,803
- Neal Rosen$21,048,001
- Mark G Kris$4,094,204
Others in their field
Top investigators on “Adenocarcinoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$39,462,948
- Anirban Maitra · Johns Hopkins University$30,605,004
- Richard M Peek · Vanderbilt University Medical Center$23,246,493
- Gloria M. Petersen · Johns Hopkins University$21,134,227
- Ronald Anthony Depinho · University Of Tx Md Anderson Can Ctr$19,098,764
- Dean E. Brenner · University Of Michigan At Ann Arbor$18,393,816
Research focus
AdenocarcinomaBaseBinding (Molecular Function)Cancer EtiologyCarcinoma, Non-Small-Cell LungC-Erbb-1 Proto-OncogenesCessation Of LifeClinical TrialsClinical Trials, Phase IiCultured CellsDasatinibDependenceDiagnosisDrug ResistanceEpidermal Growth Factor ReceptorEpidermal Growth Factor Receptor Tyrosine Kinase InhibitorErbb2 GeneErlotinibGefitinibHistologicIn VitroKillingsLeadLung Adenocarcinoma
Grant awards (4)
A Phase 2 Trial of Dasatinib in Patients with NSCLC and Acquired Resistance to Er$224,400
R21 · FY2008 · CA · contact PI
A Phase 2 Trial of Dasatinib in Patients with NSCLC and Acquired Resistance to Er$226,200
R21 · FY2007 · CA · contact PI
Molecular Determinants of Acquired Erlotinib Resistance$219,861
R21 · FY2006 · CA · contact PI
Molecular Determinants of Acquired Erlotinib Resistance$232,361
R21 · FY2005 · CA